{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:50:47Z","timestamp":1789498247329,"version":"build-2803163510"},"reference-count":25,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>We found 20 patients with an immunophenotype consistent with classic hairy cell leukemia and BRAF mutations other than just V600E. Fourteen had 1 non-V600E BRAF mutation and 6 had V600E with 1 (n\u00a0=\u00a05) or 2 (n\u00a0=\u00a01) non-V600E BRAF comutations. This study was registered at https:\/\/clinicaltrials.gov as #NCT01087333.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026894","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T19:58:38Z","timestamp":1735070318000},"page":"1957-1961","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Non-V600E <i>BRAF<\/i> mutations and treatment for hairy cell leukemia"],"prefix":"10.1182","volume":"145","author":[{"given":"Evgeny","family":"Arons","sequence":"first","affiliation":[{"name":"1Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4766-0535","authenticated-orcid":false,"given":"Chin-Hsien","family":"Tai","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2556-9194","authenticated-orcid":false,"given":"Joshi","family":"Suraj","sequence":"additional","affiliation":[{"name":"2Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1051-7236","authenticated-orcid":false,"given":"Yuelin","family":"Liu","sequence":"additional","affiliation":[{"name":"2Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"},{"name":"3Department of Computer Science, University of Maryland, College Park, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5200-2372","authenticated-orcid":false,"given":"Chi-Ping","family":"Day","sequence":"additional","affiliation":[{"name":"2Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Raffeld","sequence":"additional","affiliation":[{"name":"4Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5033-7072","authenticated-orcid":false,"given":"Liqiang","family":"Xi","sequence":"additional","affiliation":[{"name":"4Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mory","family":"Gould","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Shpilman","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristopher C.","family":"Oakes","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-0856","authenticated-orcid":false,"given":"Seema","family":"Bhat","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grever","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Jones","sequence":"additional","affiliation":[{"name":"6Department of Pathology, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry","family":"Rogers","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5408-9253","authenticated-orcid":false,"given":"Hao-Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"4Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2601-3665","authenticated-orcid":false,"given":"Constance M.","family":"Yuan","sequence":"additional","affiliation":[{"name":"4Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenk","family":"Sahinalp","sequence":"additional","affiliation":[{"name":"2Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Kreitman","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2025042411215445400_bib1","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.hoc.2006.06.012","article-title":"Immunophenotyping and differential diagnosis of hairy cell leukemia","volume":"20","author":"Matutes","year":"2006","journal-title":"Hematol Oncol Clin N Am"},{"issue":"24","key":"2025042411215445400_bib2","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025042411215445400_bib3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol"},{"issue":"21","key":"2025042411215445400_bib4","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2025042411215445400_bib5","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.1158\/1078-0432.CCR-13-1752","article-title":"Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia","volume":"19","author":"Kreitman","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"23","key":"2025042411215445400_bib6","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1182\/bloodadvances.2021005039","article-title":"Long term follow-up of a phase II study of cladribine with concurrent rituximab in patients with hairy cell leukemia variant","volume":"5","author":"Chihara","year":"2021","journal-title":"Blood Adv"},{"issue":"18","key":"2025042411215445400_bib7","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed\u00a0or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2025042411215445400_bib8","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025042411215445400_bib9","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41375-021-01210-8","article-title":"Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial","volume":"35","author":"Tiacci","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"2025042411215445400_bib10","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood.2021013658","article-title":"Dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600E mutation-positive hairy cell leukemia","volume":"141","author":"Kreitman","year":"2023","journal-title":"Blood"},{"key":"2025042411215445400_bib11","first-page":"513049","article-title":"BRAF V600E-negative hairy cell leukaemia","volume":"2013","author":"Langabeer","year":"2013","journal-title":"Case Rep Hematol"},{"issue":"9","key":"2025042411215445400_bib12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.32604\/or.2024.051218","article-title":"Non-canonical BRAF variants and rearrangements in hairy cell leukemia","volume":"32","author":"Langabeer","year":"2024","journal-title":"Oncol Res"},{"issue":"13","key":"2025042411215445400_bib13","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood-2011-10-383323","article-title":"Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia","volume":"119","author":"Schnittger","year":"2012","journal-title":"Blood"},{"issue":"14","key":"2025042411215445400_bib14","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2011-09-379339","article-title":"Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation","volume":"119","author":"Xi","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2025042411215445400_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet"},{"issue":"4","key":"2025042411215445400_bib16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.12735","article-title":"Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias","volume":"165","author":"Tschernitz","year":"2014","journal-title":"Br J Haematol"},{"issue":"17","key":"2025042411215445400_bib17","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1111\/jcmm.17890","article-title":"Hairy cell leukaemia with unusual BRAF mutations","volume":"27","author":"Maitre","year":"2023","journal-title":"J\u00a0Cell Mol Med"},{"issue":"4","key":"2025042411215445400_bib18","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/PAT.0000000000000245","article-title":"BRAF mutation detection in hairy cell leukaemia from\u00a0archival\u00a0haematolymphoid specimens","volume":"47","author":"Thomas","year":"2015","journal-title":"Pathology"},{"issue":"6","key":"2025042411215445400_bib19","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1111\/bjh.18980","article-title":"Hairy cell leukaemia with an IGH-BRAF fusion gene","volume":"202","author":"Matsumoto","year":"2023","journal-title":"Br J Haematol"},{"issue":"8","key":"2025042411215445400_bib20","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1080\/10428194.2020.1753045","article-title":"Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia","volume":"61","author":"Thompson","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025042411215445400_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41594-019-0365-0","article-title":"Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization","volume":"27","author":"Liau","year":"2020","journal-title":"Nat Struct Mol Biol"},{"issue":"14","key":"2025042411215445400_bib22","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.19.02250","article-title":"Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in\u00a0patients with hairy cell leukemia","volume":"38","author":"Chihara","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025042411215445400_bib23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2025042411215445400_bib24","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2011-04-351502","article-title":"Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia","volume":"118","author":"Ravandi","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2025042411215445400_bib25","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.14129","article-title":"Long-term durable remission by\u00a0cladribine followed by rituximab in patients with hairy cell leukaemia:\u00a0update of a phase II trial","volume":"174","author":"Chihara","year":"2016","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/17\/1957\/2370319\/blood_bld-2024-026894-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/17\/1957\/2370319\/blood_bld-2024-026894-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:22:01Z","timestamp":1745508121000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/17\/1957\/534823\/Non-V600E-BRAF-mutations-and-treatment-for-hairy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":25,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,4,24]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026894","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]}}}